Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: Long-term follow-up

Cancer

Volumn 116, Issue 15, 2010, Pages 3621-3630

  Shimoni, Avichai ^a   Hardan, Izhar ^a   Ayuk, Francis ^b   Schilling, Georgia ^b   Atanackovic, Djorde ^b   Zeller, Wolfgang ^b   Yerushalmi, Ronit ^a   Zander, Axel Rolf ^b   Kroger, Nicolaus ^b   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Allogeneic stem cell transplantation; Multiple myeloma; Reduced intensity conditioning

Indexed keywords

FLUDARABINE; MELPHALAN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE DURATION; DONOR; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECIPIENT; RECURRENT CANCER; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955366845     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25228     Document Type: Article

References (40)

1. Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009;23:442-448.
2. Gahrton G, Björkstrand B. Allogeneic transplantation in multiple myeloma. Haematologica. 2008;93:1295-1300.
3. Harousseau JL. The allogeneic dilemma. Bone Marrow Transplant. 2007;40:1123-1128.
4. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
5. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135:158-164.
6. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
7. Barlogie B, Attal M, Crowley J, Harousseau J. Long-term follow-up of autotransplant (AT)- supported high-dose melphalan (hdm) for multiple myeloma (MM):update of the Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials [abstract]. J Clin Oncol. 2009;27(suppl 1):15s. Abstract 8519.
8. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929-936.
9. Björkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711-4718. (Pubitemid 26419156)
10. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787-2793.
11. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209-216.
12. Kuruvilla J, Shepherd JD, Sutherland HJ, et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2007;13:925-931.
13. Khaled Y, Mellacheruvu S, Reddy P, Peres E, Mineishi S. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2009;44:325-326.
14. Kroger N, Perez-Simon JA, Myint H, et al. Relapse to prior autograft and chronic GVHD are the strongest prognostic factors for outcome of melphalan/fludarabine based dosereduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2004;10: 698-708.
15. Crawley C, Lalancette M, Szydlo R, et al, for the Chronic Leukaemia Working Party of the EBMT. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood. 2005;105: 4532-4539.
16. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109:3588-3594. (Pubitemid 46572554)
17. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009;113:3383-3391.
18. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-1120.
19. Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591-3593.
20. Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008; 112:3914-3915.
21. Björkstrand B, Iacobelli S, Hegenbart U, et al. Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling donor in previously untreated multiple myeloma (MM): a prospective controlled trial by the EBMT [abstract]. Bone Marrow Transplant. 2009;43(suppl 1):S31. Abstract 223.
22. Stewart AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood. 2009;113:3135-3136.
23. Madan S, Kumar S, Lacy MQ, et al. Natural history of multiple myeloma (MM) relapsing after autologous stem cell transplantation (ASCT). J Clin Oncol. 2009;27(suppl 1):Page. Abstract 19513.
24. de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant. 2008; 41:953-960.
25. Gerull S, Goerner M, Benner A, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant. 2005;36:963-969.
26. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos. 1958;53:457-481.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18: 695-706. (Pubitemid 29126745)
29. Champlin R, Khouri I, Shimoni A, et al. Harnessing graftversus- malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000; 111:18-29.
30. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322-328.
31. Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007;21:2109-2116.
32. Gahrton G, Iacobelli S, Apperley J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 2005;35:609-617.
33. Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization as prognostic factor following allogeneic dose-reduced stem cell transplantation in patients with multiple myeloma. Blood. 2004;104; 4056-4061.
34. Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008;22:1250-1255.
35. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775-5782.
36. Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102:1927-1929.
37. Ayuk F, Shimoni A, Nagler A, et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia. 2004;18:659-662. (Pubitemid 38425889)
38. Kroger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood. 2004;104:3361-3363. (Pubitemid 39507159)
39. El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93:455-458. (Pubitemid 351398650)
40. Kroger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37:791-798.